ArticleJournal of neuro-oncology2022
The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma.
Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Frailty evaluation for predicting the survival in patients with glioma: a meta-analysis.Neurosurgical review · 2025Pooled it
- Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.Journal of neuro-oncology · 2023Pooled it
- Frailty Measures for Adult Patients and Outcomes for Vestibular Schwannoma Surgeries: A Retrospective Cohort Study.Neurosurgery practice · 2026Article
- Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival.Journal of neuro-oncology · 2026Article
- A Permanent but Not Transient Postoperative Deficit Has Impact on OS and PFS in IDHwt-Glioma Patients.Journal of clinical medicine · 2026Article
- Frailty and Oncology: An Increasingly Common Combination.Cancer medicine · 2026Review
- Preoperative Temporal Muscle Volume as an Independent Prognostic Marker in Glioblastoma.Cureus · 2025Article
- Multiple Primaries: Differences in Survival of Patients with Glioma with or Without Second Malignancies.Cancers · 2025Article
- Age is not a significant predictor of survival in patients with IDH-wildtype glioblastoma that undergo gross total resection and complete adjuvant chemoradiation.Frontiers in oncology · 2025Article
- Impact of frailty on survival glioblastoma, IDH-wildtype patients.Journal of neuro-oncology · 2024Article
- Temporal Muscle Thickness Compared to Functional Scales as a Prognostic Parameter in Patients with Brain Metastases.Cancers · 2024Article
- Effect of sarcopenia and frailty on outcomes among patients with brain metastases.Journal of neuro-oncology · 2024Article
- Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Journal of neuro-oncology · 2024Article
- Temporal muscle thickness has no prognostic relevance in patients with high-grade glioma compared to functional scales.Frontiers in oncology · 2023Article
- Article
- The Clinical Frailty Scale can indicate prognosis and care requirements on discharge in oncology and haemato-oncology inpatients: A cohort study.European journal of cancer care · 2022Article
- On the value of microsurgical resection compared to biopsy in elderly glioblastoma patients: A retrospective multicenter analysis and scoring system proposal.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Clinical Frailty Scale (CFS) describes the general level of fitness or frailty and is widely used in geriatric medicine, intensive care and orthopaedic surgery. This study was conducted to analyze, whether CFS could be used for patients with high-grade glioma.
methodsPatients harboring high-grade gliomas, undergoing first resection at our center between 2015 and 2020 were retrospectively evaluated. Patients' performance was assessed using the Rockwood Clinical Frailty Scale and the Karnofsky Performance Scale (KPS) preoperatively and 3-6 months postoperatively.
results289 patients were included. Pre- as well as postoperative median frailty was 3 CFS points (IqR 2-4) corresponding to "managing well". CFS strongly correlated with KPS preoperatively (r = - 0.85; p < 0.001) and at the 3-6 months follow-up (r = - 0.90; p < 0.001). The reduction of overall survival (OS) was 54% per point of CFS preoperatively (HR 1.54, CI 95% 1.38-1.70; p < 0.001) and 58% at the follow-up (HR 1.58, CI 95% 1.41-1.78; p < 0.001), comparable to KPS. Patients with IDH mutation showed significantly better preoperative and follow-up CFS and KPS (p < 0.05). Age and performance scores correlated only mildly with each other (r = 0.21…0.35; p < 0.01), but independently predicted OS (p < 0.001 each).
conclusionCFS seems to be a reliable tool for functional assessment of patients suffering from high-grade glioma. CFS includes non-cancer related aspects and therefore is a contemporary approach for patient evaluation. Its projection of survival can be equally estimated before and after surgery. IDH-mutation caused longer survival and higher functionality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.